fda semaglutide warning The has received reports of adverse events after patients used compounded versions of semaglutide. Some compounders may also be using unapproved salt forms., Patients should avoid compounded FDA adds warning for intestinal

Disclosures: Rohit Loomba, MD, is a consultant or advisory board member for Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics

18-22 GLP-1 RAs also induce a significant reduction in body weight through delayed gastric emptying and promotion of satiety, which has led to their study in weight management

Even then, most require prior authorization and documentation of obesity severity or failed prior interventions

Research from the STEP trials shows that gastrointestinal side effects peak during dose escalation periods and then gradually subside over 1 to 2 weeks at the new dose

Final Thoughts: Listening to Your Body Every patients journey with GLP-1 medications is unique, and theres no one-size-fits-all approach

Pharmaceuticals May 30, 2024 In the realm of healthcare, the term pharmaceuticals often conjures images of neatly packaged pills produced by large-scale manufacturers